期刊
BMC CANCER
卷 18, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s12885-018-4146-7
关键词
Combined hepatocellular cholangiocarcinoma (CHCC-CC); Midkine (MK); Early recurrence; Prognosis
类别
资金
- Kaohsiung Chang Gung Memorial Hospital Taiwan [CMRPG8E0881, CMRPG8C0531, CMRPG8D0801]
Background: Post-surgical prognosis is usually poor for combined hepatocellular cholangiocarcinoma (CHCC-CC), a rare primary liver cancer. Although midkine (MK) is a prognostic biomarker for several known cancers, it is not known whether it can be used as such in resectable CHCC-CC. This study examined whether MK expression can predict recurrence and survival in patients with resectable CHCC-CC. Methods: We retrospectively enrolled 52 patients with resectable CHCC-CC who had received curative hepatic resections. MK expression was assessed in post-surgical immunohistochemical studies of specimens in paraffin blocks. Clinical outcomes were analyzed from medical records. Results: Two-year disease-free and three-year overall survival rates were 42.1% and 44.6%. MK was expressed in 30 patients. Univariate analysis showed patients positively expressing MK had a significantly poorer 2-year disease free and three-year overall survival. Multivariate analysis found positive MK expression independently predicted recurrence. Conclusions: Positive expression of MK predicts poor prognosis in patients with resectable CHCC-CC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据